EUCTR2005-004006-81-FI进行中（未招募）不适用
A double-blind, multi-center, multinational, randomized withdrawal study evaluating the efficacy and safety of SR58611A (350 mg q12) versus placebo in the prevention of depression relapse up to 1 year in patients with Major Depressive Disorder improved after 12 weeks of open treatment with SR58611A (350 mg q12) - CALYPSO
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Out-patients 18 years old or more.
- •2. Patients diagnosed with Major Depressive Disorder, Recurrent according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition - Text Revision (DSM-IV-TR) criteria and assessed with the M.I.N.I. International Neuropsychiatric Interview (MINI).
- •3. At least 1 Major Depressive Episode over the past 5 years in addition to the current episode.
- •4. The duration of the current episode (meeting full DSM-IV-TR criteria) is between 4 weeks and 2 years.
- •5. With a total score on the Montgomery and Asberg Depression Rating Scale
- •(MADRS) = 28.
- •6. Patients have given voluntarily their written informed consent to participate in the
- •whole maintenance study.
- •7. Able to comply with the protocol and follow written and verbal instructions.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients at immediate risk for suicidal behavior based on an unstructured clinical interview; or who have, before first study drug intake [at either the screening (V1) or baseline (V2) visits]:
- •- A score of >5 on the suicidal thoughts item of the MADRS
- •- Or a current suicide risk score > or equal to 10 from module C of the MINI
- •2. Patients with a major depressive episode with psychotic features, catatonic features, seasonal pattern or postpartum onset according to MINI at screening.
- •3. Patients with 3 or more episodes of depression in the last 3 years.
- •4. The course of the current depressive episode is longer than 2 years.
- •5. For the current episode, patients failed to respond to an adequate dose of an
- •antidepressant given for 6 weeks.
- •6. Patients with mood disorder due to general medical conditions (degenerative
- •neurological conditions, cerebrovascular disease, endocrine conditions, viral or other
- •infections).
- •7. Patients with a lifetime history according to MINI at screening of:
- •- bipolar disorder or psychotic disorder,
- •- panic disorder,
- •- antisocial personality disorder.
- •8. Patients with a current history according to MINI at screening of:
- •- alcohol dependence or abuse or substance dependence or abuse in the past
- •12 months, except nicotine or caffeine dependence,
- •- eating disorders.
- •9. Introduction of, or change in intensity of psychotherapy from 3 months prior to
- •10. Treatment with a MAO Inhibitor (during one week or more) within 2 weeks prior to screening.
- •11. Treatment with fluoxetine (during one week or more) within 4 weeks prior to
- •12. Chronic use of hypnotics / benzodiazepines. Chronic means more than 2 days per
- •week during the previous month.
- •13. Patients who have received Electro-Convulsive Therapy (ECT) for the previous Major Depressive Episode.
- •14. Patients who received any antipsychotic drugs in the last 4 weeks prior to screening.
- •15. Patients with severe or unstable concomitant medical conditions (cardiovascular,
- •neurologic, gastrointestinal, hepatic, renal, endocrinologic, rheumatologic) according
- •to the investigator's judgment that would impact the assessment of the study drug.
- •16. History of seizures other than a single childhood febrile seizure.
- •17. Patients with abnormal thyroid functioning, i.e. TSH blood level at screening out of normal range, unless patients are taking a hormone replacement therapy at a stable dose for at least 3 months prior to baseline.
- •18. Patients with clinically significant abnormal laboratory value at screening, e.g. ALT or AST > 2 times upper limit of normal range (ULN), hemoglobin < 12g / 100ml for
- •male and < 11g / 100ml for female, neutrophils < 1500/mm3, platelets < 100 000/mm3, creatinine = 150 µmol/l.
- •19. Patients with clinically significant ECG findings at screening.
- •20. Patients with positive results on the urine drug screen at screening.
- •21. Patients who have taken an investigational drug in the last 3 months prior to screening.
- •22. Any subject who has previously participated in a SR58611A protocol.
- •23. Women who are pregnant or breast-feeding; women of childbearing potential who are not using a medically accepted means of contraception when engaging in sexual intercourse: for example intrauterine device, oral contraceptives, implant, hormonal injection, barrier devices or barrier devices with spermicide.
研究者
相似试验
已完成
不适用
A multicentre, multinational, double blind, randomised, parallel group, placebo-controlled study of ethyl-eicosapentaenoate (EPA) in patients with Huntington's disease (HD)Huntington's diseaseNervous System DiseasesISRCTN79170611axdale Ltd (UK)
进行中（未招募）
不适用
A multicentre, multinational, double-blind, randomised, parallel group, placebo controlled trial of ethyl-EPA ethyl-Icosapent in patients with Huntington s Disease - NDEUCTR2005-002088-98-ITAMARIN NEUROSCIENCE LTD240
进行中（未招募）
不适用
A double blind, multicentre, multinational, randomized, double dummy, three-arm parallel-group comparative study of the efficacy, safety and tolerance of oral NXL103 (500 mg twice daily) versus NXL103 (600 mg twice daily) versus oral amoxicillin (1000 mg three times daily) in the treatment of community-acquired pneumonia in adultsCommunity-Acquired PneumoniaEUCTR2007-001735-66-DEovexel S. A.300
进行中（未招募）
不适用
A double blind, multicentre, multinational, randomized, double dummy, three-arm parallel-group comparative study of the efficacy, safety and tolerance of oral NXL103 (500 mg twice daily) versus NXL103 (600 mg twice daily) versus oral amoxicillin (1000 mg three times daily) in the treatment of community-acquired pneumonia in adultsMedDRA version: 9.1Level: LLTClassification code 10010120Term: Community acquired pneumoniaCommunity-Acquired PneumoniaEUCTR2007-001735-66-EEovexel S. A.300
已完成
不适用
A multi-center, multi-national, double-blind, randomized, active-controlled, parallel-group clinical study to assess safety and efficacy of PDA10 (epoetin-alfa) compared to Eprex® in patients with anemia of chronic renal failureDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0006024PanGen Biotech316